ADCYAP1 and ischemic disease: In the last three decades numerous studies have examined the protective effect of PACAP in several ischemic diseases based on its antiapoptotic, anti-inflammatory and general cytoprotective effects [12,13,14], suggesting the applicability of PACAP as a potential cardiac biomarker, especially in pathologies with ischemic etiology [15,16,17,18].